Ed Arce
Stock Analyst at HC Wainwright & Co.
(3.65)
# 766
Out of 4,868 analysts
486
Total ratings
43.39%
Success rate
7.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Assumes: Buy | $30 | $14.21 | +111.12% | 21 | Jun 11, 2025 | |
| MTVA MetaVia | Reiterates: Buy | $12 | $0.70 | +1,614.78% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $7.5 | $5.50 | +36.36% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $12.15 | +393.83% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $3.59 | +109.21% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $3.36 | +287.02% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $2.50 | - | 17 | Apr 2, 2025 | |
| TLPH Talphera | Reiterates: Buy | $6 | $0.48 | +1,150.65% | 6 | Apr 1, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $7.91 | +784.96% | 6 | Mar 31, 2025 | |
| DRRX DURECT | Reiterates: Neutral | n/a | $0.68 | - | 13 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $17.11 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $0.62 | +1,838.61% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.28 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $7.61 | +320.50% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $35 | $20.66 | +69.45% | 22 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $75 | $54.65 | +37.24% | 25 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $29 → $21 | $10.03 | +109.37% | 22 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $50.07 | +43.81% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $281.03 | +44.11% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $3.60 | +52.99% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $36.76 | +158.47% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $7.03 | +156.23% | 11 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $3.92 | +231.82% | 18 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $3.40 | +47.28% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $17.83 | +169.21% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $4.04 | +85.64% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.99 | +403.22% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $7.76 | +67.53% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 → $240 | $0.67 | +35,914.41% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.26 | - | 8 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $20.88 | +19.73% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.83 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $19.81 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $26.00 | -73.08% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $29.25 | -28.21% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.24 | - | 2 | Feb 15, 2017 |
Travere Therapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $30
Current: $14.21
Upside: +111.12%
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $12
Current: $0.70
Upside: +1,614.78%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $7.5
Current: $5.50
Upside: +36.36%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $12.15
Upside: +393.83%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $3.59
Upside: +109.21%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $3.36
Upside: +287.02%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $2.50
Upside: -
Talphera
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.48
Upside: +1,150.65%
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $7.91
Upside: +784.96%
DURECT
Mar 27, 2025
Reiterates: Neutral
Price Target: n/a
Current: $0.68
Upside: -
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $17.11
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $12
Current: $0.62
Upside: +1,838.61%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.28
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $7.61
Upside: +320.50%
Mar 10, 2025
Maintains: Buy
Price Target: $24 → $35
Current: $20.66
Upside: +69.45%
Mar 3, 2025
Maintains: Buy
Price Target: $72 → $75
Current: $54.65
Upside: +37.24%
Feb 28, 2025
Reiterates: Buy
Price Target: $29 → $21
Current: $10.03
Upside: +109.37%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $50.07
Upside: +43.81%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $281.03
Upside: +44.11%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $3.60
Upside: +52.99%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $36.76
Upside: +158.47%
Feb 11, 2025
Reiterates: Buy
Price Target: $18
Current: $7.03
Upside: +156.23%
Feb 7, 2025
Reiterates: Buy
Price Target: $13
Current: $3.92
Upside: +231.82%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $3.40
Upside: +47.28%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $17.83
Upside: +169.21%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $4.04
Upside: +85.64%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $0.99
Upside: +403.22%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $7.76
Upside: +67.53%
Mar 26, 2024
Reiterates: Buy
Price Target: $12 → $240
Current: $0.67
Upside: +35,914.41%
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.26
Upside: -
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $20.88
Upside: +19.73%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.83
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $19.81
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $26.00
Upside: -73.08%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $29.25
Upside: -28.21%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.24
Upside: -